Association between case management and longitudinal decrease in negative symptoms in patients with first episode psychosis: A 2-year follow-up.

Abstract

AIM:

Negative symptoms (NS) severely affect daily functioning already at the psychosis onset. However, most studies investigating beneficial effects of specific treatments for NS mainly included individuals with prolonged psychotic disorders. Furthermore, evidence on psychosocial rehabilitation for NS in early psychosis is still relatively poor. The aims of this study therefore were (A) to longitudinally examine NS stability in people with first episode psychosis (FEP) along a 2-year follow-up period, and (B) to overtime explore any relevant association of NS levels with the specific intervention components of an 'early intervention in psychosis' (EIP) protocol during the follow-up.

METHODS:

At baseline, 266 FEP subjects (aged 12-35 years) completed the positive and negative syndrome scale (PANSS). Multiple linear regression analyses were then performed.

RESULTS:

Along the follow-up, FEP participants had a relevant improvement in NS levels. This was specifically predicted by the total number of case management sessions offered within our 2-year EIP protocol, as well as by shorter duration of untreated psychosis at entry and by longitudinal reduction in PANSS depressive and positive symptom dimension levels. No association with antipsychotic medication was found.

CONCLUSIONS:

NS are clinically relevant in FEP, already at the recruitment time in specialized EIP services. However, their severity appears to improve over time together with the delivery of patient-tailored, integrated EIP case management.

• Authors: Lorenzo Pelizza, Davide Maestri, Emanuela Leuci, Emanuela Quattrone, Silvia Azzali, Giuseppina Paulillo, Pietro Pellegrini
• Journal: Early intervention in psychiatry (Early Interv Psychiatry) Vol. 16 Issue 11 Pg. 1185-1191 (11 2022) ISSN: 1751-7893 [Electronic] Australia
• PMID: 35086160 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 John Wiley & Sons Australia, Ltd.

Chemical References

• Antipsychotic Agents

Topics

• Humans
• Follow-Up Studies
• Case Management
• Psychotic Disorders (diagnosis, drug therapy)
• Antipsychotic Agents (therapeutic use)
• Time Factors